CCND1 and melanoma: The evidence that approximately 20–38% of melanoma show CCND1 amplification, thus potentially being primarily resistant to BRAFi, has suggested that adding a CDK4/6 inhibitor could enhance the efficacy of BRAFi and MEKi [92,93].